SEC EDGARSEP 181 min read$CORT

Vieira Roberto Wandenkolk sold $30K of CORT

Vieira Roberto Wandenkolk (President, Oncology) sold 296 shares of CORCEPT THERAPEUTICS INC (CORT) at $100.82 on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Vieira Roberto Wandenkolk

Published Sep 18, 2026, 11:53 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 18, 2026, 11:54 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CORT

Neutral

high confidence

Mentioned

$CORT

Relevance

2/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CORTNeutralLow

Why it matters

The disclosed sale is modest and pre-arranged, suggesting no immediate market impact.

Market read

Routine insider sale with limited trading relevance.

What to watch

Potential upcoming clinical data could change relevance of insider activity.

Relevance 2/10Novelty 3/10Timing: filed Sep 18 2026

Background

Form 4 filing reports insider transactions required by SEC; provides transparency on insider holdings.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CORTNeutralHigh confidence

Context

Officer sold 296 shares for $29,842.72 via 10b5-1 plan on Sep 16, 2026.

Expected impact

No material impact expected.

Evidence & confidence

Sale size is small relative to float and disclosed via pre-arranged plan.

Market effects

Sector

None; isolated insider transaction.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor future filings.

Key entities

Company
Corcept Therapeutics Inc.
Biopharma company developing cortisol receptor antagonists.
Insider
Vieira Roberto Wandenkolk
President, Oncology at Corcept Therapeutics.

Read at source ← All news

SEP 22

$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

insidermonkey.com3 min

SEP 19

$CORTHighAI 8/10

CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally

Corcept Therapeutics (CORT) shares rose 7% to their highest 2026 levels after announcing plans to resubmit its NDA for Relacorilant, a Cushing’s syndrome treatment, following positive FDA discussions. The FDA rejected the initial filing in December, citing insufficient effectiveness data. The company expects a PDUFA date six months post-submission. CORT shares are down 27% year-to-date, with retail sentiment remaining bearish.

stocktwits.com2 min

SEP 18

$CORTMedAI 8/10

Corcept's Lifyorli Gets Positive EU Opinion For Platinum-Resistant Ovarian Cancer

Corcept Therapeutics (CORT) announced that the EMA's CHMP recommended approval of relacorilant for platinum-resistant ovarian cancer, based on Phase 2 and 3 trial data showing improved survival rates. The European Commission will decide by Q4 2026. CORT's stock closed at $114.86, up 2.73%, and was at $115.45 in premarket trading.

rttnews.com2 min

SEP 18

$CORTHighAI 9/10

Corcept Therapeutics Incorporated: Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli (Relacorilant)

Corcept Therapeutics (CORT) announced the European Medicines Agency's CHMP recommended EU approval for relacorilant, combined with nab-paclitaxel, to treat platinum-resistant ovarian cancer. The recommendation follows positive Phase 2 and Phase 3 trial results showing improved survival rates. The EC will decide by Q4 2026. Relacorilant is already FDA-approved in the U.S. for the same indication.

finanznachrichten.de2 min

AUG 6

$CORTHighAI 9/10

Raised Guidance Lifts Corcept to 52-Week High

Corcept Therapeutics (CORT) reported fiscal 2026 Q2 results with record revenue of $256.1 million, up 32% year over year, and net income of $43 million, up 22.9%. The company had $545 million in cash and investments and raised 2026 revenue guidance to as much as $1.2 billion, sending shares to a 52-week high.

yahoo.com3 min

JUL 31

$MSFTHighAI 8/10

Stocks Rally on Stellar Microsoft Earnings and Chip Stock Strength

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.

yahoo.com7 min